Susquehanna International Group
URGN icon

Susquehanna International Group’s UroGen Pharma URGN Stock Holding History

Susquehanna International Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.12M Sell
118,000
-48,900
-29% -$980K ﹤0.01% 6045
2025
Q4 		$3.91M Sell
166,900
-202,800
-55% -$4.4M ﹤0.01% 4432
2025
Q3 		$7.38M Sell
369,700
-116,600
-24% -$2.09M ﹤0.01% 3470
2025
Q2 		$6.66M Buy
486,300
+466,100
+2,307% +$4.47M ﹤0.01% 3473
2025
Q1 		$223K Buy
+20,200
New +$215K ﹤0.01% 10716
2024
Q4 		– Sell
-12,200
Closed -$155K – 13287
2024
Q3 		$155K Sell
12,200
-47,300
-79% -$702K ﹤0.01% 10712
2024
Q2 		$998K Buy
59,500
+35,000
+143% +$498K ﹤0.01% 6599
2024
Q1 		$368K Buy
+24,500
New +$400K ﹤0.01% 9236
2023
Q4 		– Sell
-13,900
Closed -$195K – 13346
2023
Q3 		$195K Buy
+13,900
New +$223K ﹤0.01% 10259
2023
Q2 		– Sell
-35,500
Closed -$328K – 13184
2023
Q1 		$328K Sell
35,500
-7,400
-17% -$68.1K ﹤0.01% 9515
2022
Q4 		$381K Buy
42,900
+21,400
+100% +$203K ﹤0.01% 8518
2022
Q3 		$179K Buy
+21,500
New +$178K ﹤0.01% 10997
2020
Q4 		– Sell
-25,500
Closed -$492K – 11766
2020
Q3 		$492K Sell
25,500
-11,900
-32% -$269K ﹤0.01% 7713
2020
Q2 		$977K Sell
37,400
-87,100
-70% -$2.13M ﹤0.01% 5984
2020
Q1 		$2.22M Buy
124,500
+25,000
+25% +$675K ﹤0.01% 3792
2019
Q4 		$3.32M Buy
99,500
+49,900
+101% +$1.36M ﹤0.01% 3537
2019
Q3 		$1.18M Buy
49,600
+9,500
+24% +$311K ﹤0.01% 5328
2019
Q2 		$1.44M Buy
40,100
+2,700
+7% +$99.5K ﹤0.01% 4869
2019
Q1 		$1.38M Buy
37,400
+29,400
+368% +$1.23M ﹤0.01% 4372
2018
Q4 		$344K Buy
+8,000
New +$360K ﹤0.01% 6752

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group's URGN Position: Q1 2026 in Review

Susquehanna International Group reduced its UroGen Pharma (URGN) stake by 49% in Q1 2026, selling an estimated $1.59M and leaving 83,623 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #6868.

Susquehanna International Group first reported a position in URGN in Q3 2018 and has held it in 23 quarters since. The position peaked at $6.64M in Q2 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Susquehanna International Group held 83,623 shares of UroGen Pharma worth $1.5M as of Q1 2026.
  • Susquehanna International Group sold 79,102 UroGen Pharma shares in Q1 2026, an estimated $1.59M.
  • UroGen Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6868 holding.
  • Susquehanna International Group first reported a position in UroGen Pharma in Q3 2018 and has held it in 23 quarters since.
  • Susquehanna International Group's UroGen Pharma position peaked at $6.64M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.